Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco Galaxy Bitcoin ETF (BTCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco Galaxy Bitcoin ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Invesco Galaxy Bitcoin ETF trades at $62.92. Which is the better fit depends on your goals.
| ALNY | BTCO | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Crypto-linked |
52-Week High | $491.22 | $125.14 |
52-Week Low | $205.48 | $58.40 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
BTCO shares trade at $63.00, down 0.97% with technical indicators showing a bullish bias despite mixed signals. The stock faces resistance at $65 with support at $64, while moving averages suggest upward momentum. Recent market sentiment reflects cautious optimism amid broader financial market volatility.
The stock's outlook remains uncertain with technical strength countered by fundamental data gaps. Investment opportunity hinges on upcoming financial disclosures, while risks include market volatility and competitive pressures in the company's sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →
